• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Merck - Articles and news items

globe-pill

GSK tops list ranking big pharma’s global access to medicine

Industry news / 14 November 2016 / Niamh Louise Marriott, Digital Content Producer

Read how the 2016 Access to Medicine Index ranks the top 20 pharmaceutical companies on their efforts to improve access to medicine in low- and middle-income countries…

pill-cost-effective

NICE says head and neck cancer drug cetuximab is not cost-effective

Industry news / 7 November 2016 / Niamh Louise Marriott, Digital Content Producer

NICE was reconsidering cetuximab as part of its programme to appraise drugs that are currently available on the Cancer Drugs Fund…

global-rights-multiple

Apitope regains global rights to its multiple sclerosis treatment from Merck

Industry news / 18 October 2016 / Niamh Louise Marriott, Digital Content Producer

In 2009, Apitope granted exclusive worldwide rights to Merck to develop and commercialise ATX-MS-1467 but now have successfully regained…

eu hepatitis c european market

MSD’s Hepatitis C drug given green light for EU market

Industry news / 9 August 2016 / MSD

Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with genotype 1 and 4 infection…

FDA Merck approval head and neck cancer

FDA approves Merck’s head and neck cancer drug

Industry news / 8 August 2016 / Merck

Under the FDA’s accelerated approval regulations, Keytruda, a humanized monoclonal antibody that works by increasing the ability of the body’s immune system to help detect and fight tumour cells, is approved based on tumour response rate and durability of response. However, continued approval for the drug may be contingent upon verification and description of clinical benefit in the confirmatory trials…

keytruda

CHMP positive opinion for Keytruda in NSCLC

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

The CHMP has recommended approval of Keytruda for the treatment of locally advanced or metastatic NSCLC in adults whose tumours express PD-L1…

ECHO-301

First patient treated in the Phase III ECHO-301 study

Industry news / 23 June 2016 / Victoria White, Digital Content Producer

ECHO-301 will evaluate Incyte’s epacadostat with Merck’s pembrolizumab as first-line treatment for patients with advanced or metastatic melanoma…

relebactam

Phase II study of relebactam in UTIs meets primary endpoint

Industry news / 21 June 2016 / Victoria White, Digital Content Producer

The addition of relebactam is designed to restore activity of imipenem against certain imipenem-resistant strains of Gram-negative bacteria…

KEYNOTE-024

Keytruda superior to chemotherapy in NSCLC study

Industry news / 17 June 2016 / Victoria White, Digital Content Producer

The KEYNOTE-024 trial investigating Keytruda in patients with previously untreated advanced non-small cell lung cancer has met its primary endpoint…

type 2 diabetes

Ertugliflozin shows significant A1C reductions in type 2 diabetes

Industry news / 14 June 2016 / Victoria White, Digital Content Producer

Two studies of ertugliflozin, an investigational oral SGLT-2 inhibitor for the treatment of patients with type 2 diabetes, met their primary endpoints…

MK-1293

MK-1293 shows non-inferiority to Lantus in two Phase III studies

Industry news / 14 June 2016 / Victoria White, Digital Content Producer

Merck has announced results from two Phase III studies evaluating MK-1293 for the treatment of people with type 1 and type 2 diabetes…

afferent

Merck to acquire Afferent Pharmaceuticals

Industry news / 10 June 2016 / Victoria White, Digital Content Producer

Merck, known as MSD outside the US and Canada, has announced that it is is to acquire Afferent Pharmaceuticals…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +